Brief: Island Pharmaceuticals Says FDA Advises It Requires Additional Time To Finalise Response To Co's Submission
05/01/2026 01:18
Jan 5 (Reuters) - Island Pharmaceuticals Ltd ILA.AX: FDA ADVISES IT REQUIRES ADDITIONAL TIME TO FINALISE RESPONSE TO CO'S RECENT SUBMISSION CO HAD SOUGHT FURTHER CLARIFICATION ON GALIDESIVIR'S DEVELOPMENT PATHWAY UNDER FDA'S ANIMAL RULE Further company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic